• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Survey Shows U.S. Trials Embracing Direct-to-Patient Shipment of Supplies

Survey Shows U.S. Trials Embracing Direct-to-Patient Shipment of Supplies

May 10, 2021

Sponsors say direct-to-patient (DTP) distribution of clinical supplies, including investigational drugs, is an important service to offer and nearly two-thirds say it’s essential to successful execution of a clinical trial, according to a new survey, especially as trials become more virtual.

When asked how likely they are to run remote, or home-based, clinical trials that would include remote monitoring of patients through point-of-care devices and testing within the next two to three years, 27 percent of sponsors said between 1 percent and 15 percent of their future studies will be remote, while 25 percent answered that between 15 percent and 30 percent of their studies will be remote. Another 18 percent of respondents said more than 30 percent of their future studies will be remote within that time frame, while 23 percent said they had no plans to run remote studies and 8 percent said they already were.

Catalent and FiercePharma surveyed 234 individuals involved in clinical supply and operations at sponsor companies. Their survey shows sponsors are also more appreciative of the way DTP distribution, often in the form of patient kits, can optimize clinical site operations and improve supply-chain efficiency. Thirty-four percent of sponsors said better inventory management and the ability to pool supplies centrally was the biggest benefit of using a central pharmacy located within the same site as their clinical distribution hub or depot, rather than using a clinical site pharmacist or an off-site central pharmacy to dispense DTP kits. Another 24 percent of respondents said shorter supply chains and fewer handoffs were the most important benefit, while 21 percent said the potential for reducing the number of clinical sites and pharmacists were the biggest perceived gain.

Read the survey here: https://sforce.co/3h8739c.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing